Abstract
Cyclin-Dependent Kinases 4 (CDK4) belongs to a family of serine-threonine protein kinase and plays key regulatory role in G1-phase of cell cycle progression. Compelling evidences have shown that targeting CDK4 pathway is an attractive proposition for tumor therapy. Recent progresses of selective small molecule CDK4 inhibitors in cancer therapy have endorsed the field to be interested and attractive. In this review, we will discuss the recent developments of CDK4 inhibitors on several aspects such as the structure of CDK4, the working mechanism of CDK4 inhibitors, the structure activity relationships (SARs) of the selective CDK4 inhibitors and the latest developments of the selective CDK4 inhibitors in clinical trials.
Keywords: Anti-cancer agents, cell cycle, clinical trials, cyclin-dependent kinases 4, selective inhibitors, structure activity relationship (SAR).
Anti-Cancer Agents in Medicinal Chemistry
Title:Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Volume: 17 Issue: 5
Author(s): Haixing Guan, Yongli Du*, Weiwei Han, Jingkang Shen*Qunyi Li
Affiliation:
- School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, 3501 Daxue Road, Jinan 250353,China
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203,China
Keywords: Anti-cancer agents, cell cycle, clinical trials, cyclin-dependent kinases 4, selective inhibitors, structure activity relationship (SAR).
Abstract: Cyclin-Dependent Kinases 4 (CDK4) belongs to a family of serine-threonine protein kinase and plays key regulatory role in G1-phase of cell cycle progression. Compelling evidences have shown that targeting CDK4 pathway is an attractive proposition for tumor therapy. Recent progresses of selective small molecule CDK4 inhibitors in cancer therapy have endorsed the field to be interested and attractive. In this review, we will discuss the recent developments of CDK4 inhibitors on several aspects such as the structure of CDK4, the working mechanism of CDK4 inhibitors, the structure activity relationships (SARs) of the selective CDK4 inhibitors and the latest developments of the selective CDK4 inhibitors in clinical trials.
Export Options
About this article
Cite this article as:
Guan Haixing, Du Yongli*, Han Weiwei, Shen Jingkang*, Li Qunyi, Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (5) . https://dx.doi.org/10.2174/1871520617666170103095527
DOI https://dx.doi.org/10.2174/1871520617666170103095527 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Current Medicinal Chemistry Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Cystine Dimethyl Ester Induces Apoptosis Through Regulation of PKC-δ and PKC-ε in Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Current Cancer Therapy Reviews A Comprehensive Review on Pharmacology and Toxicology of Bioactive Compounds of <i>Lagerstroemia Speciosa(L.</i>) Pers.
Current Traditional Medicine Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design Polyphyllin I Induces Cell Cycle Arrest and Cell Apoptosis in Human Retinoblastoma Y-79 Cells through Targeting p53
Anti-Cancer Agents in Medicinal Chemistry Understanding FOXO, New Views on Old Transcription Factors
Current Cancer Drug Targets The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract
Current Drug Targets Bladder Cancer: Update on Risk Factors, Molecular and Ultrastructural Patterns
Current Medicinal Chemistry In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Disordered Interactome of Human Papillomavirus
Current Pharmaceutical Design